Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT04752722
Registration number
NCT04752722
Ethics application status
Date submitted
4/02/2021
Date registered
12/02/2021
Date last updated
11/06/2025
Titles & IDs
Public title
LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
Query!
Scientific title
A Phase 1/2 Study of EG-70 as an Intravesical Administration to Patients With BCG Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) and High-Risk NMIBC Patients Who Are BCG Naïve or Received Incomplete BCG Treatment
Query!
Secondary ID [1]
0
0
EG-70-101
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Superficial Bladder Cancer
0
0
Query!
Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Bladder - transitional cell cancer
Query!
Renal and Urogenital
0
0
0
0
Query!
Other renal and urogenital disorders
Query!
Cancer
0
0
0
0
Query!
Cervical (cervix)
Query!
Cancer
0
0
0
0
Query!
Breast
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - EG-70 (phase 1)
Treatment: Drugs - EG-70 (phase 2)
Experimental: Phase 1 - Dose escalation phase
Experimental: Phase 2 - Cohort 1: Recommended Phase 2 dose (RP2D) with eligible BCG-unresponsive NMIBC patients with CIS, up to 4 cycles of treatment with EG-70
Cohorts 2A, 2B and 3: RP2D with eligible high-risk NMIBC patients with CIS who are BCG-naïve, BCG-exposed (incompletely treated with BCG) or BCG-unresponsive HG Ta/T1 papillary disease without CIS
Treatment: Drugs: EG-70 (phase 1)
Patients will receive up to four cycles of EG-70 administered as a bladder instillation of a 50 mL volume of study drug via catheter with a targeted retention time of 60 minutes.One cycle lasts approximately 12 weeks and consists of either a 2-dose (Day 1 and Day 8) or 4-dose (Day 1, Day 8, Day 29 and Day 36) regimen.
Treatment: Drugs: EG-70 (phase 2)
Patients will receive during Treatment Period, up to 4 cycles of EG-70 at the RP2D defined in Phase 1 administered as a bladder instillation of a 50 mL volume of study drug via catheter with a targeted retention time of 60 minutes. One cycle lasts approximately 12 weeks. For Maintenance treatment 2 doses of EG-70 will be administered as a bladder instillation per 12-week cycle.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Phase 1: Nature, incidence, relatedness, and severity of all AEs and SAEs according to the CTCAE v5.0.
Query!
Assessment method [1]
0
0
The type, incidence, relatedness and severity of treatment emergent adverse events of EG-70 as assessed by NCI-CTCAE V5.0 will be monitored.
Query!
Timepoint [1]
0
0
Approximately 2 years
Query!
Primary outcome [2]
0
0
Phase 2: Percentage of patients with cystoscopic CR at 48 weeks, based on exam, urine cytology and appropriate biopsies.
Query!
Assessment method [2]
0
0
Complete response rate will be measured by determining the number of patients without recurrence of high-grade disease.
Query!
Timepoint [2]
0
0
Approximately 48 weeks
Query!
Primary outcome [3]
0
0
Phase 2: Nature, incidence, relatedness, and severity of treatment emergent adverse events (as assessed by CTCAE v5.0)
Query!
Assessment method [3]
0
0
The type, incidence, relatedness and severity of treatment emergent adverse events of EG-70 as assessed by NCI-CTCAE V5.0 will be monitored.
Query!
Timepoint [3]
0
0
Approximately 3 years
Query!
Secondary outcome [1]
0
0
Phase 1: The number of patients who experience a DLT through the end of Cycle 1
Query!
Assessment method [1]
0
0
To identify the number of patients who experience a DLT through the end of Cycle 1
Query!
Timepoint [1]
0
0
Approximately 12 Weeks
Query!
Secondary outcome [2]
0
0
Phase 1: CR rate to EG-70 by cystoscopy at approximately 12 weeks.
Query!
Assessment method [2]
0
0
To evaluate preliminary efficacy of EG-70 by 12 weeks via cystoscopy
Query!
Timepoint [2]
0
0
Approximately 12 weeks
Query!
Secondary outcome [3]
0
0
Phase 2: Progression-free survival (PFS)
Query!
Assessment method [3]
0
0
To evaluate disease-free survival rate
Query!
Timepoint [3]
0
0
Approximately 3 years
Query!
Secondary outcome [4]
0
0
Phase 2: CR rate at 12, 24, 36, and 96 weeks
Query!
Assessment method [4]
0
0
To further evaluate CR at the efficacy analysis following each cycle.
Query!
Timepoint [4]
0
0
Approximately 12, 24, 36, and 96 weeks
Query!
Secondary outcome [5]
0
0
Phase 2: Duration of response of the responding patients
Query!
Assessment method [5]
0
0
Durability will be measured by determining the number of patients without recurrence of high-grade disease.
Query!
Timepoint [5]
0
0
Approximately 3 years
Query!
Secondary outcome [6]
0
0
Phase 2: Quality of Life Assessment
Query!
Assessment method [6]
0
0
Health-related quality of life
Query!
Timepoint [6]
0
0
24 weeks
Query!
Eligibility
Key inclusion criteria
BCG-unresponsive Patients:
1. BCG-unresponsive NMIBC with carcinoma in situ (CIS) with or without coexisting papillary Ta/T1 tumors who are ineligible for or have elected not to undergo cystectomy, and have experienced CIS disease within 12 months of treatment where: adequate BCG regimen consists of at least 2 courses of BCG where the first course (induction) must have included at least 5 or 6 doses and the second course may have included a re-induction (at least 2 treatments) or maintenance (at least 2 doses), and Cis must be documented or indicated by pathology
Phase 2 Only:
2. BCG-Naïve or BCG-incompletely treated Patients with CIS or BCG-unresponsive, HG Ta/T1 papillary disease without CIS:
-NMIBC with current Cis of the bladder, with or without coexisting papillary Ta/T1 NMIBC tumor(s), who are ineligible for or have elected not to undergo cystectomy, where: either: cohort 2a) no treatment with BCG but may have previously been treated with at least 1 dose of intravesical chemotherapy following transurethral resection of bladder tumor (TURBT) and Cis must be documented or cohort 2b) indicated by pathology incomplete BCG treatment (at least 1 dose and less than the 5+2 doses required for adequate dosing per Cohort 1) or cohort 3) patients who are BCG-unresponsive following adequate treatment, with HG Ta/T1 papillary disease without CIS.
All Patients:
3. Patients who have previously been treated with a checkpoint inhibitor and failed treatment are eligible for inclusion 30 days post-treatment (Phase 1) or 3 months post-treatment (Phase 2).
4. Male or non-pregnant, non-lactating female, 18 years or older.
5. Women of childbearing potential must have a negative pregnancy test at Screening.
6. Female patients of childbearing potential must be willing to consent to using highly effective birth control methods; Male patients are required to utilize a condom for the duration of the study treatment through 3 months post-dose.
7. In Phase 2, for patients with T1 lesions may be eligible after repeat TURBT if pathology shows non-invasive (Ta or less) or no disease.
8. Performance Status: Eastern Cooperative Oncology Group 0, 1, and 2.
9. Hematologic inclusion: a. Absolute neutrophil count >1,500/mm3. b. Hemoglobin >9.0 g/dL. c. Platelet count >100,000/mm3.
10. Hepatic inclusion: a. Total bilirubin must be =1.5 x the upper limit of normal (ULN). b. Aspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline phosphatase =2.5 x ULN.
11. Adequate renal function with creatinine clearance >30 mL/min
12. Prothrombin time and partial thromboplastin time =1.25 x ULN or within the therapeutic range if on anticoagulation therapy.
13. Must have satisfactory bladder function with ability to retain study drug for 60 minutes.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
1. Active malignancies (i.e., progressing or requiring treatment change in the last 24 months). Exceptions allowed under Sponsor review.
2. Concurrent treatment with any chemotherapeutic agent.
3. History of partial cystectomy.
4. Treatment with last therapeutic agent (including intravesical chemotherapy post-TURBT) within 30 days of Screening (prior to the screening biopsy).
5. Patients who have received systemic immunosuppressive medication including high-dose corticosteroids.
6. History of severe asthma or other respiratory diseases.
7. History of unresolved vesicoureteral reflux or an indwelling urinary stent.
8. History of unresolved hydronephrosis due to ureteral obstruction.
9. Participation in any other research protocol involving administration of an investigational agent within 30 Days prior to screening or any prior treatment of NMIBC with any investigational gene or immunotherapy agent.
10. History of external beam radiation to the pelvis or prostate brachytherapy within the last 12 months.
11. History of interstitial lung disease and/or pneumonitis in patients who have previously received a PD-1 or PD-L1 inhibitor therapy.
12. Evidence of metastatic disease.
13. History of difficult catheterization that in the opinion of the Investigator will prevent administration of EG-70.
14. Active interstitial cystitis on cystoscopy or biopsy.
15. Active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy.
16. Known human immunodeficiency virus, Hepatitis B, or Hepatitis C infection.
17. Significant cardiovascular risk (e.g., coronary stenting within 8 weeks, myocardial infarction within 6 months).
18. Hypersensitivity to any of the excipients of the study drug.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Other
Query!
Other design features
Query!
Phase
Phase 1
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
22/04/2021
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
30/11/2028
Query!
Actual
Query!
Sample size
Target
350
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
NSW,SA
Query!
Recruitment hospital [1]
0
0
Sydney Adventist Hospital - Wahroonga
Query!
Recruitment hospital [2]
0
0
Icon Cancer Center Windsor Gardens - Windsor Gardens
Query!
Recruitment postcode(s) [1]
0
0
2076 - Wahroonga
Query!
Recruitment postcode(s) [2]
0
0
5087 - Windsor Gardens
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arizona
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arkansas
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
California
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Colorado
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
District of Columbia
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Florida
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Georgia
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Illinois
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Indiana
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Kansas
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Maryland
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Massachusetts
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Michigan
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Minnesota
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
New Jersey
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
New York
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
North Carolina
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Ohio
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
Oregon
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
South Carolina
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
Tennessee
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
Texas
Query!
Country [23]
0
0
United States of America
Query!
State/province [23]
0
0
Virginia
Query!
Country [24]
0
0
United States of America
Query!
State/province [24]
0
0
Wisconsin
Query!
Country [25]
0
0
Canada
Query!
State/province [25]
0
0
Alberta
Query!
Country [26]
0
0
Canada
Query!
State/province [26]
0
0
British Columbia
Query!
Country [27]
0
0
Canada
Query!
State/province [27]
0
0
Nova Scotia
Query!
Country [28]
0
0
Canada
Query!
State/province [28]
0
0
Quebec
Query!
Country [29]
0
0
France
Query!
State/province [29]
0
0
Bordeaux
Query!
Country [30]
0
0
France
Query!
State/province [30]
0
0
Lille
Query!
Country [31]
0
0
Germany
Query!
State/province [31]
0
0
Duisburg
Query!
Country [32]
0
0
Germany
Query!
State/province [32]
0
0
Mettmann
Query!
Country [33]
0
0
Italy
Query!
State/province [33]
0
0
MI
Query!
Country [34]
0
0
Italy
Query!
State/province [34]
0
0
Milano
Query!
Country [35]
0
0
Italy
Query!
State/province [35]
0
0
Napoli
Query!
Country [36]
0
0
Italy
Query!
State/province [36]
0
0
Rome
Query!
Country [37]
0
0
Korea, Republic of
Query!
State/province [37]
0
0
Gyunggi-do
Query!
Country [38]
0
0
Korea, Republic of
Query!
State/province [38]
0
0
Jeollanam-do
Query!
Country [39]
0
0
Korea, Republic of
Query!
State/province [39]
0
0
Seoul
Query!
Country [40]
0
0
Spain
Query!
State/province [40]
0
0
Barberà Del Vallès
Query!
Country [41]
0
0
Spain
Query!
State/province [41]
0
0
Barcelona
Query!
Country [42]
0
0
Spain
Query!
State/province [42]
0
0
Madrid
Query!
Country [43]
0
0
Spain
Query!
State/province [43]
0
0
Murcia
Query!
Country [44]
0
0
Spain
Query!
State/province [44]
0
0
Santander
Query!
Country [45]
0
0
Taiwan
Query!
State/province [45]
0
0
Kaohsiung
Query!
Country [46]
0
0
Taiwan
Query!
State/province [46]
0
0
Taichung
Query!
Country [47]
0
0
Taiwan
Query!
State/province [47]
0
0
Tainan city
Query!
Country [48]
0
0
Taiwan
Query!
State/province [48]
0
0
Taipei City
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
enGene, Inc.
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This study will evaluate the safety and efficacy of intravesical administration of EG-70 in the bladder and its effect on bladder tumors in patients with NMIBC. This study study consists of two phases; a Phase 1 dose-escalation to establish safety and recommended the phase 2 dose, followed by a Phase 2 study to establish how effective the treatment is. The Study will include patients with NMIBC with Cis for whom BCG therapy is unresponsive and patients with NMIBC with Cis who are BCG-naïve or inadequately treated.
Query!
Trial website
https://clinicaltrials.gov/study/NCT04752722
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Christine Tosone, Ms, RAC
Query!
Address
0
0
enGene, Inc.
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
enGene clinical trials
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
+18572991097
Query!
Fax
0
0
Query!
Email
0
0
clinicaltrials@engene.com
Query!
Contact person for scientific queries
Data sharing statement
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results not provided in
https://clinicaltrials.gov/study/NCT04752722
Download to PDF